原发性高脂血症患者血脂康调脂有效性临床再评价  

Reassessment of Lipid Regulating Effect of Xuezhikang on Primary Hyperlipidemia Patients: A Systematic Review

作　　者：杜建平[1] 赵自明[1] 夏能能[1] 任薇[1] 

机构地区：[1]广东省第二中医院(广东省中医药工程技术研究院)中医药信息研究室,广州510095

出　　处：《华西医学》2015年第2期254-262,共9页West China Medical Journal

摘　　要：目的通过文献分析系统评价血脂康1.2 g/d治疗4周对干预原发性高脂血症患者血脂含量的有效性。方法计算机检索1994年1月1日-2014年8月30日中国知网、万方和维普三大中文全文数据库,筛选关于1.2 g/d血脂康连续给药4周后对原发性高脂血症患者血脂含量影响的自身对照试验,采用Rev Man 5.2软件对资料进行Meta分析。结果共纳入55篇独立研究;所纳入独立研究均不具有同质性(P<0.01,I2均>70%),且均存在发表性偏倚;1.2 g/d血脂康治疗4周后,高脂血症患者总胆固醇(TC)、三酰甘油(TG)、低密度脂蛋白胆固醇(LDL-C)较治疗前均降低,差异有统计学意义[WMD=1.14 mmol/L,95%CI(1.02,1.25)mmol/L,P<0.000 01;WMD=0.72 mmol/L,95%CI(0.59,0.85)mmol/L,P<0.000 01;WMD=0.87 mmol/L,95%CI(0.74,1.00)mmol/L,P<0.000 01],高密度脂蛋白胆固醇(HDL-C)较治疗前提高,差异有统计学意义[WMD=-0.16 mmol/L,95%CI(-0.26,-0.12)mmol/L,P<0.000 01]。结论血脂康1.2 g/d治疗4周后可显著降低原发性高脂血症患者TC、TG、LDL-C,提高HDL-C。Objective To assess the effect of Xuezhikang 1.2 g/d after 4 weeks＇ treatment on primary hyperlipidemia patients＇ lipid contents including total cholesterol （TC）, triglyceride （TG）, low density lipoprotein cholesterol （LDL-C） and high density lipoprotein cholesterol （HDL-C） by literature analysis. Methods A literature research was carried out in CNKI, Wanfang and Weipu full-text database to collect articles published from January 1st, 1994 to August 30 th, 2014, concerning the self-controlled trials on the lipid regulating effects of Xuezhikang 1.2 g/d for 4 weeks in primary hyperlipidemia patients. Statistical analysis was performed with Review Manager 5.2. Results Fif^- five independent trials were included in this review. All of the independent studies showed no homogeneity （P 〈 0.01, I2 〉 70%）, and had publication bias. The contents of TC, TG, and LDL-C after a 4-week treatment with 1.2 g/d Xuezhikang were significantly lower than those before treatment [WMD=l.14 mmol/L, 95%CI （1.02, 1.25） mmol/L, P 〈 0.000 01; WMD=0.72 mmol/L, 95%CI （0.59, 0.85） mmol/L, P 〈 0.000 01; WMD=0.87 mmol/L, 95%CI （0.74, 1.00） mmol/L, P 〈 0.000 01] and the contents of HDL-C was significantly higher than that before treatment [WMD=-0.16 mmol/L, 95%CI （-0.26, -0.12） mmol/L, P 〈 0.000 01]. Conclusion Xuezhikang can reduce the primary hypedipidemia patients＇ TC, TG and LDL-C, and increase HDL-C after 4 weeks＇ treatment.

关 键 词：血脂康 调脂 原发性高脂血症 系统评价 

分 类 号：R589.2[医药卫生—内分泌]